Zabofloxacin

Source: Wikipedia, the free encyclopedia.
Zabofloxacin
Names
Preferred IUPAC name
1-Cyclopropyl-6-fluoro-7-[(8E)-8-(methoxyimino)-2,6-diazaspiro[3.4]octan-6-yl]-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
Other names
DW-224a
Identifiers
3D model (
JSmol
)
ChemSpider
UNII
  • InChI=1S/C19H20FN5O4/c1-29-23-14-6-24(9-19(14)7-21-8-19)17-13(20)4-11-15(26)12(18(27)28)5-25(10-2-3-10)16(11)22-17/h4-5,10,21H,2-3,6-9H2,1H3,(H,27,28)/b23-14-
    Key: ZNPOCLHDJCAZAH-UCQKPKSFSA-N
  • InChI=1/C19H20FN5O4/c1-29-23-14-6-24(9-19(14)7-21-8-19)17-13(20)4-11-15(26)12(18(27)28)5-25(10-2-3-10)16(11)22-17/h4-5,10,21H,2-3,6-9H2,1H3,(H,27,28)/b23-14-
    Key: ZNPOCLHDJCAZAH-UCQKPKSFBL
  • Fc1c(nc2c(c1)C(=O)C(\C(=O)O)=C/N2C3CC3)N5C\C(=N\OC)C4(CNC4)C5
Properties
C19H20FN5O4
Molar mass 401.392
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

Zabofloxacin (DW-224a) is an investigational

fluoroquinolone antibiotic for multidrug-resistant infections due to Gram-positive bacteria.[1][2][3][4] It also has activity against Neisseria gonorrhoeae including strains that are resistant to other quinolone antibiotics.[5]

Zabofloxacin was discovered by Dong Wha Pharmaceuticals and licensed to Pacific Beach BioSciences for development.[6]

A double-blind, three-arm clinical study of the drug began in March 2010.[7]

References

External links